basal cell carcinoma

Managing hedgehog therapies for basal cell carcinomaWhile the vast majority of basal cell carcinomas are treated and resolved with surgery, systemic therapy with one of the two hedgehog pathway inhibitors could be a treatment option for unresectable or metastasized disease, researchers reported at the American Academy of Dermatology annual meeting in San Diego this week.
Repurposed antifungal exhibits promising results
Repurposed antifungal exhibits promising resultsA novel oral formulation of itraconazole designed to improve bioavailability is leveraging its activity as a Hedgehog pathway inhibitor to provide a low toxicity, effective treatment for patients with BCC Nevus Syndrome. Data show potential for rapid therapeutic benefit.
Sonidegib gets a new label for recurring laBCCSun Pharmaceutical Industries announced in September the FDA has approved a new label for sonidegib (Odomzo, Novartis), an oral hedgehog inhibitor indicated for the treatment of adults with locally advanced basal cell carcinoma (laBCC) that has recurred following surgery or radiation therapy, or for patients who are not candidates for surgery or radiation therapy.
New pathways to cancer therapyA novel oral formulation of itraconazole (SUBA-Itraconazole, HedgePath Pharmaceuticals) is providing dramatic benefit for patients with basal cell carcinoma nevus syndrome (BCCNS, also known as Gorlin syndrome) and with a favorable safety profile, according to a recent interim analysis of data collected in a phase IIb study.
Skin cancer quick reference
Skin cancer quick referenceThe May Table of the Month goes over tips for properly diagnosing skin cancer types.
Skin cancer advancesGenetic profiling is valuable in both diagnosis and prognosis of skin cancer. Hedgehog inhibitors and (superficial radiation therapy) SRT are strong contenders for treating nonmelanoma skin cancer. Advances in targeted therapies and biologics are part of the new wave of melanoma treatments.
Psoriasis and skin cancerCyclosporine and PUVA clearly increase the risk of squamous cell carcinomas, and there is evidence that TNF blockers and methotrexate may do so to a lesser degree. UVB phototherapy has not been shown to cause skin cancer. Acitretin offers protection against the development of basal cell and squamous cell carcinomas.
Update on advanced basal cell carcinoma diagnosis and treatmentDespite increased insight on skin cancer risk factors, the incidence continues to rise worldwide. This review article summarizes new treatment options available, which help to redefine and expand the diagnosis of advanced BCC and allow dermatologists to offer more effective therapy to a broader population.
Staying current with therapeutic advances and expert insightsThis month we offer new insights and data to aid diagnosis and treatment of difficult conditions, as well as practical approaches to optimize outcomes.
Vismodegib study confirms safety, efficacy for BCCThe largest-ever vismodegib study in advanced basal cell carcinoma, the STEVIE study, confirms pivotal study findings in a real-world setting, helping dermatologists to provide a complete palette of skin cancer treatments.